We thank all the patients, their families, and the investigators who participated in the current study. We also thank Dr. Ali Nasermoaddeli (Taiho Pharmaceutical Co Ltd.) for his important contributions to the management of this study from a medical perspective.

**Data Availability Statement:** Data generated or analyzed during this study are on file with Taiho Pharmaceutical Co Ltd and are not publicly available. Inquiries for data access may be sent to the following email address: <TOIAWASE@taiho.co.jp>.

Introduction {#cncr32429-sec-0005}
============

Chemotherapy‐induced nausea and vomiting (CINV) is a common side effect related to cancer treatment, thereby making the prevention of CINV very important. Antiemetic guidelines have recommended the use of combinations of 3 or 4 prophylactic agents, including dexamethasone, 5‐hydroxytryptamine 3 (5‐HT~3~) receptor antagonists (RAs), neurokinin 1 (NK~1~) RAs, and olanzapine for the prevention of CINV in patients receiving highly emetogenic chemotherapy (HEC).[1](#cncr32429-bib-0001){ref-type="ref"}, [2](#cncr32429-bib-0002){ref-type="ref"}, [3](#cncr32429-bib-0003){ref-type="ref"} With NK~1~ RAs, the use of an intravenous formulation can improve compliance compared with an oral formulation because intravenous agents are administered only on the day of chemotherapy. However, fosaprepitant, which is an intravenously administered NK~1~ RA, may cause infusion site reactions (ISRs).[4](#cncr32429-bib-0004){ref-type="ref"} To expand the treatment options for the prevention of CINV, new agents are required.

Fosnetupitant is a phosphorylated prodrug of netupitant, which has high selectivity and an affinity for the NK~1~ receptor. Netupitant is marketed as NEPA (a fixed oral combination of netupitant at a dose of 300 mg and palonosetron at a dose of 0.5 mg) worldwide, except in Japan. The optimal dose of fosnetupitant is 235 mg (corresponding to a 260‐mg dose of fosnetupitant chloride hydrochloride), which is the bioequivalent of netupitant at a dose of 300 mg in terms of area under the exposure time curve.[5](#cncr32429-bib-0005){ref-type="ref"} Fosnetupitant in combination with palonosetron (at a dose of 0.25 mg intravenously), NEPA for injection, was approved for the prevention of acute and delayed CINV associated with HEC in the United States based on bioequivalence data and on a phase 3 safety study in initial and repeated cycles in \>400 patients.[6](#cncr32429-bib-0006){ref-type="ref"}

A phase 1 study in healthy adults in Japan demonstrated that fosnetupitant was well tolerated up to a dose of 353 mg and confirmed that fosnetupitant rapidly converts to netupitant after administration.[7](#cncr32429-bib-0007){ref-type="ref"} A phase 2 study of oral netupitant in Japanese patients receiving HEC assessed the dose‐response relationship using 3 doses (30 mg, 100 mg, and 300 mg). However, the dose‐response relationship and efficacy of netupitant could not be clearly demonstrated because a placebo was not included for comparison.[8](#cncr32429-bib-0008){ref-type="ref"} Therefore, we considered that the inclusion of a placebo arm was needed to confirm the efficacy of fosnetupitant.

The primary endpoint of the current study was to determine the fosnetupitant dose superior to placebo. To the best of our knowledge, the current study represents the first efficacy study in the development of fosnetupitant as a single agent. To this aim, the efficacy and safety of a single dose of fosnetupitant of 81 mg (corresponding to fosnetupitant chloride hydrochloride at a dose of 90 mg) or 235 mg was compared with placebo plus palonosetron at a dose of 0.75 mg and dexamethasone in Japanese patients receiving cisplatin‐based HEC.

Materials and Methods {#cncr32429-sec-0006}
=====================

Study Design {#cncr32429-sec-0007}
------------

The current multicenter, randomized, double‐blind, placebo‐controlled, parallel group phase 2 study was conducted at 74 institutions in Japan. Study sites are listed in Supporting Table [S1](#cncr32429-sup-0001){ref-type="supplementary-material"}. The study was approved by the institutional review board of each participating institution and was performed in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines. All patients provided written informed consent before study enrollment.

This trial was registered with Clinical Trial Registration (number Japic CTI‐163355).

Patients {#cncr32429-sec-0008}
--------

Patients aged ≥20 years who had a confirmed malignant solid tumor, were scheduled to receive cisplatin at a dose of ≥70 mg/m^2^, and had received no chemotherapy or prior low or minimally emetogenic chemotherapy regimen were eligible. Patients were required to have an Eastern Cooperative Oncology Group performance status of 0 or 1 and adequate hematologic, hepatic, and renal function.

Patients were excluded if they had gastrointestinal stenosis; any vomiting, retching, or nausea within 24 hours prior to enrollment; severe complications, infection, or diabetes mellitus that could be associated with difficulties with the administration of dexamethasone; or hypersensitivity to NK~1~ RAs, 5‐HT~3~ RAs, or dexamethasone. Patients who had received a cytochrome P450 3A4 inhibitor or inducer, had received an opioid analgesic, had undergone surgery, or had undergone radiotherapy within 7 days before registration and pregnant and nursing women also were excluded.

Treatment {#cncr32429-sec-0009}
---------

Patients were randomly assigned using the minimization method, stratified by sex and age class (age \<55 years vs age ≥55 years), to receive placebo or fosnetupitant at a dose of 81 mg or 235 mg. The study drug and palonosetron at a dose of 0.75 mg were administered intravenously approximately 60 minutes prior to the administration of cisplatin and infused for 30 minutes on day 1. The dose of palonosetron of 0.75 mg is approved in Japan based on the study.[9](#cncr32429-bib-0009){ref-type="ref"} Dexamethasone (at a dose of 9.9 mg for the fosnetupitant group and 13.2 mg for the placebo group) was administered intravenously 60 minutes prior to the administration of cisplatin. On days 2 to 4, dexamethasone at a dose of 6.6 mg was administered intravenously in the morning. Because dexamethasone exposure is increased when given in combination with fosnetupitant, the dose of dexamethasone in the groups of patients receiving fosnetupitant was reduced to achieve dexamethasone exposure similar to that in the placebo group.

Rescue medication was permitted at the discretion of the investigators for the treatment of vomiting or nausea during the 168 hours after the initiation of cisplatin. Aprepitant, fosaprepitant, palonosetron, and/or dexamethasone were not permitted as rescue medications.

During the study, treatment assignment was masked from all patients, investigators, and study personnel except for the pharmacists who were preparing the study drugs at the institutions, who were prohibited from divulging any information regarding drug assignment.

Endpoints {#cncr32429-sec-0010}
---------

The primary endpoint of the current study was the percentage of patients with a complete response (CR; no emesis and no rescue medication) during the overall phase (0‐120 hours after cisplatin administration). The secondary endpoints were the percentages of patients with CR during the acute (0‐24 hours) and delayed (24‐120 hours) phases, and during 24 to 168 hours after cisplatin administration as well as complete protection (CR plus no more than mild nausea); total control (CR plus no nausea); and no vomiting, no nausea, and no significant nausea during the acute, delayed, and overall phases as well as during 24 to 168 hours after the initiation of cisplatin. Other secondary endpoints were the rates of adverse events (AEs) and the frequency of ISRs.

Assessment {#cncr32429-sec-0011}
----------

All patients were hospitalized for an 8‐day observation period after the administration of cisplatin. They recorded episodes of nausea and vomiting every 24 hours in a diary. An emetic episode was defined as ≥1 continuous episodes of vomiting and retching. The severity of nausea was measured using a 4‐point Likert scale (none, mild, moderate, or severe).

AEs were assessed by the investigators according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03). ISRs were evaluated after study drug administration in patients without central venous access devices.

Pharmacokinetics {#cncr32429-sec-0012}
----------------

Blood samples were obtained for the evaluation of fosnetupitant and netupitant pharmacokinetics (PKs) from at least 10 patients in each group at the following time points: before dosing and at 0.25, 0.5, 0.75, 1, 2, 3, 5, 8, 24, 48, 72, 120, and 168 hours after administration of the study drug. Plasma samples were prepared by centrifugation of the blood samples. Fosnetupitant and netupitant concentrations in the plasma samples were determined using validated liquid chromatography/tandem mass spectrometry methods. The PK parameters shown in Supporting Table [S2](#cncr32429-sup-0001){ref-type="supplementary-material"} were calculated from the obtained plasma concentration profiles.

Statistical Analysis {#cncr32429-sec-0013}
--------------------

The primary objective of the current study was to demonstrate the superiority of fosnetupitant over placebo in terms of the percentage of patients who achieved a CR during the overall phase in the full analysis set, which comprised all patients who received cisplatin, the study drug, palonosetron, and dexamethasone on day 1. For the primary efficacy analysis, the overall CR rates were estimated using the logistic regression model with the stratification factors of sex and age class (age \<55 years vs age ≥55 years) as covariates by marginal standardization[10](#cncr32429-bib-0010){ref-type="ref"} and compared between each fosnetupitant dose group and the placebo group at an overall 2‐sided significance level of 5% by statistical testing assuming normality. Testing was adjusted for multiplicity using the Hochberg method to maintain the overall 2‐sided significance level at 5%. Under the assumption that overall CR rates were 65% for fosnetupitant and 50% for placebo based on a previous phase 2 study of fosnetupitant,[11](#cncr32429-bib-0011){ref-type="ref"} a phase 2 study of netupitant conducted in Japan,[8](#cncr32429-bib-0008){ref-type="ref"} and a phase 3 study of palonosetron,[9](#cncr32429-bib-0009){ref-type="ref"} a sample size of 185 evaluable patients per group (585 in total, considering the possibility of dropouts) was determined to ensure a power of at least 80% for each comparison in the primary analysis.

Safety was analyzed in the as‐treated population, which included all patients who received the study drug.

PK parameters were determined for fosnetupitant and netupitant. Each PK parameter was evaluated in the fosnetupitant groups.

Statistical analysis was performed using SAS statistical software (version 9.4; SAS Institute Inc, Cary, North Carolina) and WinNonlin (version 7.0; Certara LP, Princeton, New Jersey) for PKs only.

Results {#cncr32429-sec-0014}
=======

A total of 594 patients were randomized between September 5, 2016, and November 24, 2017. Seven patients did not receive the study treatment (Fig. [1](#cncr32429-fig-0001){ref-type="fig"}). The baseline characteristics of the full analysis set were similar across the placebo and fosnetupitant 81‐mg dose and 235‐mg dose groups (Table [1](#cncr32429-tbl-0001){ref-type="table"}). In addition, 17 patients and 10 patients, respectively, in the fosnetupitant 81‐mg dose and 235‐mg dose groups were evaluated for PKs. The baseline characteristics of the PK population were similar to those in the full analysis set (data not shown).

![Consolidated Standards Of Reporting Trials (CONSORT) diagram.](CNCR-125-4076-g001){#cncr32429-fig-0001}

###### 

Baseline Patient Characteristics: Full Analysis Set

                                                       Placebo N = 194   Fosnetupitant at a Dose of 81 mg N = 195   Fosnetupitant at a Dose of 235 mg N = 195
  ---------------------------------------------------- ----------------- ------------------------------------------ -------------------------------------------
  Sex, no. (%)                                                                                                      
  Male                                                 147 (75.8)        146 (74.9)                                 148 (75.9)
  Female                                               47 (24.2)         49 (25.1)                                  47 (24.1)
  Age, y                                                                                                            
  Median                                               67.0              66.0                                       67.0
  Range                                                36‐79             41‐76                                      37‐78
  Age category, no. (%)                                                                                             
  \<55 y                                               24 (12.4)         25 (12.8)                                  22 (11.3)
  ≥55 y                                                170 (87.6)        170 (87.2)                                 173 (88.7)
  Drinking history, no. (%)                                                                                         
  No                                                   71 (36.6)         70 (35.9)                                  67 (34.4)
  Rarely (once per mo)                                 18 (9.3)          22 (11.3)                                  23 (11.8)
  Occasionally                                         18 (9.3)          21 (10.8)                                  24 (12.3)
  Regularly                                            87 (44.8)         82 (42.1)                                  81 (41.5)
  Smoking history, no. (%)                                                                                          
  Nonsmoker                                            41 (21.1)         33 (16.9)                                  40 (20.5)
  Stopped smoking prior to 180 d before registration   82 (42.3)         88 (45.1)                                  87 (44.6)
  Stopped smoking within 180 d before registration     51 (26.3)         63 (32.3)                                  52 (26.7)
  Smoker                                               20 (10.3)         11 (5.6)                                   16 (8.2)
  ECOG performance status, no. (%)                                                                                  
  0                                                    124 (63.9)        125 (64.1)                                 113 (57.9)
  1                                                    70 (36.1)         70 (35.9)                                  82 (42.1)
  Cancer type, no. (%)                                                                                              
  Lung                                                 184 (94.8)        184 (94.4)                                 187 (95.9)
  Other                                                10 (5.2)          11 (5.6)                                   8 (4.1)
  Prior systemic drug therapies, no. (%)                                                                            
  No                                                   175 (90.2)        175 (89.7)                                 167 (85.6)
  Yes                                                  19 (9.8)          20 (10.3)                                  28 (14.4)
  Chemotherapy regimen, no. (%)                                                                                     
  Cisplatin plus vinorelbine tartrate                  69 (35.6)         66 (33.8)                                  56 (28.7)
  Cisplatin plus pemetrexed                            56 (28.9)         57 (29.2)                                  63 (32.3)
  Cisplatin plus pemetrexed plus bevacizumab           29 (14.9)         32 (16.4)                                  29 (14.9)
  Cisplatin plus etoposide                             24 (12.4)         21 (10.8)                                  24 (12.3)
  Cisplatin plus other cancer treatment                16 (8.2)          19 (9.7)                                   23 (11.8)

Abbreviation: ECOG, Eastern Cooperative Oncology Group.
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Efficacy {#cncr32429-sec-0015}
--------

The overall CR rates were 54.7%, 63.8%, and 76.8%, respectively, in the placebo, fosnetupitant 81‐mg dose, and fosnetupitant 235‐mg dose groups. There was not a statistically significant difference noted between the fosnetupitant 81‐mg dose and placebo groups (adjusted difference, 9.1%; 95% CI, ‐0.4% to 18.6% \[*P* = .061; 2‐sided significance level = .05\]). The overall CR rate in the fosnetupitant 235‐mg dose group was statistically superior to that in the placebo group (adjusted difference, 22.0%; 97.5% CI, 11.7% to 32.3% \[*P* \< .001; 2‐sided significance level = .025\]).

The CR rates for each observation period are shown in Figure [2](#cncr32429-fig-0002){ref-type="fig"}. The CR rates for the acute and delayed phases and for the period of 24 to 168 hours were higher in the fosnetupitant 235‐mg dose group compared with the placebo group. The rates of all secondary efficacy endpoints were higher in the fosnetupitant 235‐mg dose group compared with the placebo group (see Supporting Table [S3](#cncr32429-sup-0001){ref-type="supplementary-material"}). The rate of "no nausea" in the delayed phase was approximately 15 percentage points higher in the fosnetupitant 235‐mg dose group (56.4%) compared with the placebo group (41.2%).

![Percentage of patients achieving a complete response in the overall (0‐120 hours), acute (0‐24 hours), and delayed (24‐120 hours) phases and during 24 to 168 hours after cisplatin administration (full analysis set). \* indicates the primary endpoint.](CNCR-125-4076-g002){#cncr32429-fig-0002}

Safety {#cncr32429-sec-0016}
------

The incidences of AEs and serious AEs were similar between the 3 groups (see Supporting Table [S4](#cncr32429-sup-0001){ref-type="supplementary-material"}). The incidences of AEs and treatment‐related AEs were similar between the 3 treatment groups, with no tendency noted for the rates of AEs to increase in a dose‐dependent manner (Table [2](#cncr32429-tbl-0002){ref-type="table"}). Treatment‐related AEs with an incidence ≥5% were constipation (13.8%, 14.2%, and 16.4%, respectively, in the placebo and fosnetupitant 81‐mg dose and 235‐mg dose groups) and hiccups (4.6%, 7.1%, and 5.6%, respectively, in the placebo and fosnetupitant 81‐mg dose and 235‐mg dose groups). ISR‐related AEs were all grade 1 or 2, and there was no tendency for the rate to increase in a dose‐dependent manner (5.7%, 10.8%, and 7.9%, respectively, in the placebo and fosnetupitant 81‐mg dose and 235‐mg dose groups). The incidences of treatment‐related injection site thrombophlebitis and injection site discomfort were similar between the 3 treatment groups (Table [3](#cncr32429-tbl-0003){ref-type="table"}).

###### 

AEs and Treatment‐Related AEs Occurring in at Least 5% of Patients in Each Treatment Group: As‐Treated Population[a](#cncr32429-note-0007){ref-type="fn"}

  AE                                   AE           Treatment‐Related AE                                        
  ------------------------------------ ------------ ---------------------- ------------ ----------- ----------- -----------
  Anemia                               10 (5.1)     17 (8.6)               11 (5.6)     0 (0.0)     0 (0.0)     0 (0.0)
  Febrile neutropenia                  3 (1.5)      11 (5.6)               6 (3.1)      0 (0.0)     0 (0.0)     0 (0.0)
  Leukopenia                           8 (4.1)      9 (4.6)                14 (7.2)     0 (0.0)     0 (0.0)     1 (0.5)
  Neutropenia                          18 (9.2)     28 (14.2)              27 (13.8)    0 (0.0)     1 (0.5)     1 (0.5)
  Hyperglycemia                        5 (2.6)      5 (2.5)                10 (5.1)     0 (0.0)     0 (0.0)     0 (0.0)
  Hyponatremia                         7 (3.6)      20 (10.2)              17 (8.7)     0 (0.0)     6 (3.0)     3 (1.5)
  Decreased appetite                   78 (40.0)    78 (39.6)              71 (36.4)    2 (1.0)     6 (3.0)     8 (4.1)
  Insomnia                             21 (10.8)    20 (10.2)              12 (6.2)     1 (0.5)     1 (0.5)     1 (0.5)
  Dysgeusia                            7 (3.6)      11 (5.6)               12 (6.2)     0 (0.0)     2 (1.0)     0 (0.0)
  Headache                             4 (2.1)      9 (4.6)                13 (6.7)     0 (0.0)     4 (2.0)     4 (2.1)
  Hiccups                              64 (32.8)    65 (33.0)              80 (41.0)    9 (4.6)     14 (7.1)    11 (5.6)
  Upper abdominal pain                 5 (2.6)      13 (6.6)               10 (5.1)     0 (0.0)     1 (0.5)     0 (0.0)
  Constipation                         120 (61.5)   128 (65.0)             129 (66.2)   27 (13.8)   28 (14.2)   32 (16.4)
  Diarrhea                             10 (5.1)     19 (9.6)               20 (10.3)    1 (0.5)     2 (1.0)     1 (0.5)
  Nausea                               25 (12.8)    31 (15.7)              23 (11.8)    0 (0.0)     2 (1.0)     1 (0.5)
  Stomatitis                           8 (4.1)      11 (5.6)               13 (6.7)     0 (0.0)     2 (1.0)     0 (0.0)
  Vomiting                             11 (5.6)     3 (1.5)                1 (0.5)      0 (0.0)     0 (0.0)     0 (0.0)
  Injection site pain                  8 (4.1)      14 (7.1)               11 (5.6)     0 (0.0)     0 (0.0)     0 (0.0)
  Malaise                              24 (12.3)    25 (12.7)              32 (16.4)    2 (1.0)     1 (0.5)     3 (1.5)
  Alanine aminotransferase increased   8 (4.1)      11 (5.6)               11 (5.6)     3 (1.5)     5 (2.5)     8 (4.1)
  Blood creatinine increased           10 (5.1)     15 (7.6)               6 (3.1)      1 (0.5)     1 (0.5)     0 (0.0)
  Neutrophil count decreased           59 (30.3)    56 (28.4)              56 (28.7)    0 (0.0)     0 (0.0)     1 (0.5)
  Platelet count decreased             17 (8.7)     18 (9.1)               16 (8.2)     0 (0.0)     1 (0.5)     0 (0.0)
  White blood cell count decreased     42 (21.5)    46 (23.4)              43 (22.1)    0 (0.0)     0 (0.0)     1 (0.5)

Abbreviation: AE, adverse event.

Shown as the number of patients (%).

AEs reported by the investigator were coded using MedDRA/J (version 20.1). A treatment‐related AE was an AE judged by the investigator to be related, most likely related, or possibly related to the study drug.

Assessed using National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03).

John Wiley & Sons, Ltd

###### 

Summary of Infusion Site Reactions in Patients Without a Central Venous Access Device Among the As‐Treated Population

  Patients With AEs at the Infusion Site   AEs[a](#cncr32429-note-0010){ref-type="fn"}   Treatment‐Related AEs[a](#cncr32429-note-0010){ref-type="fn"}                                  
  ---------------------------------------- --------------------------------------------- --------------------------------------------------------------- ---------- --------- --------- ---------
  Total ISRs                               11 (5.7)                                      21 (10.8)                                                       15 (7.9)   0 (0.0)   1 (0.5)   2 (1.0)
  Injection site pain                      8 (4.1)                                       14 (7.2)                                                        11 (5.8)   0 (0.0)   0 (0.0)   0 (0.0)
  Injection site erythema                  5 (2.6)                                       3 (1.5)                                                         0 (0.0)    0 (0.0)   0 (0.0)   0 (0.0)
  Injection site induration                3 (1.6)                                       2 (1.0)                                                         0 (0.0)    0 (0.0)   0 (0.0)   0 (0.0)
  Injection site thrombophlebitis          0 (0.0)                                       3 (1.5)                                                         3 (1.6)    0 (0.0)   1 (0.5)   1 (0.5)
  Injection site reaction                  0 (0.0)                                       2 (1.0)                                                         0 (0.0)    0 (0.0)   0 (0.0)   0 (0.0)
  Injection site discomfort                0 (0.0)                                       0 (0.0)                                                         1 (0.5)    0 (0.0)   0 (0.0)   1 (0.5)

Abbreviations: AE, adverse event; ISR, infusion site reaction.

Data are shown as the number of patients (%).

Assessed using National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03).

John Wiley & Sons, Ltd

Pharmacokinetics {#cncr32429-sec-0017}
----------------

The mean concentration‐time profiles of fosnetupitant and netupitant in plasma for the 2 fosnetupitant doses are illustrated in Supporting Figure [S1](#cncr32429-sup-0001){ref-type="supplementary-material"}. A summary of the PK parameters for each dose is presented in Supporting Table [S2](#cncr32429-sup-0001){ref-type="supplementary-material"}. Fosnetupitant was eliminated rapidly from plasma after administration. The plasma concentration of netupitant reached a maximum at the end of the infusion and then declined gradually, with a mean elimination half‐life of 69.5 to 82.7 hours. Exposure to netupitant increased in a dose‐dependent manner.

Discussion {#cncr32429-sec-0018}
==========

In the current study, the addition of a single intravenous dose of 235 mg of fosnetupitant to palonosetron and dexamethasone demonstrated superiority to palonosetron and dexamethasone alone with respect to the overall CR rate for patients receiving cisplatin‐based HEC. Fosnetupitant at a dose of 235 mg consistently was found to be more effective than placebo and fosnetupitant at a dose of 81 mg across all secondary efficacy endpoints and demonstrated an acceptable safety profile. The adjusted difference in the overall CR rate between the fosnetupitant 81‐mg dose group and the placebo group was not statistically significant.

In a previous phase 2 study of oral netupitant that was conducted outside Japan, superiority versus placebo was demonstrated for all doses (100 mg, 200 mg, and 300 mg), but clear differences were not observed between the netupitant dose groups.[11](#cncr32429-bib-0011){ref-type="ref"} There are several potential reasons for this difference between the 2 studies. First, the prescribed cisplatin dose was different. The previous phase 2 study of oral netupitant enrolled patients receiving cisplatin at a dose of ≥50 mg/m^2^,[11](#cncr32429-bib-0011){ref-type="ref"} whereas the current study enrolled patients receiving cisplatin at a dose of ≥70 mg/m^2^. The difference in the treatment effect between (fos)netupitant doses might be more notable when administered with a cisplatin dose of ≥70 mg/m^2^ compared with a dose of ≥50 mg/m^2^.[12](#cncr32429-bib-0012){ref-type="ref"} Second, the dose and formulation of palonosetron differed between the 2 studies (intravenous 0.75 mg in the current study vs an oral dose of 0.5 mg in the previous study[11](#cncr32429-bib-0011){ref-type="ref"}). Oral palonosetron at a dose of 0.5 mg is comparable to intravenous palonosetron at a dose of 0.25 mg.[13](#cncr32429-bib-0013){ref-type="ref"} Palonosetron at a dose of 0.75 mg demonstrated better efficacy in the delayed and overall phases compared with the dose of 0.25 mg in the previous study conducted in Japan,[14](#cncr32429-bib-0014){ref-type="ref"} and therefore a lower fosnetupitant dose of 81 mg might not provide sufficient additional efficacy to demonstrate superiority over the placebo group in this setting.

Although the CR rate in the acute phase in the group treated with fosnetupitant was comparable to that reported with other NK~1~ RA‐containing regimens, the additional effect of fosnetupitant on "no nausea" in the delayed phase was higher than that observed with other NK~1~ RAs. Although patients treated with aprepitant and fosaprepitant improved by 5.9 to 8.7 percentage points,[15](#cncr32429-bib-0015){ref-type="ref"}, [16](#cncr32429-bib-0016){ref-type="ref"} the patients treated with fosnetupitant at a dose of 235 mg improved by approximately 15 percentage points with regard to experiencing no nausea in the delayed phase versus patients receiving placebo. Given that \>50% of patients enrolled in the current study were male, aged \>55 years, and had an alcohol history, such a population might not be considered as group at an extremely high risk of developing CINV. However, the patient characteristics of the current study such as sex and age were not largely different from those of the previous studies of aprepitant and fosaprepitant.[15](#cncr32429-bib-0015){ref-type="ref"}, [16](#cncr32429-bib-0016){ref-type="ref"} A prospective registration study performed by the CINV Study Group of Japan reported that the incidence and severity of nausea peaked on days 4 to 5 among patients receiving cisplatin.[17](#cncr32429-bib-0017){ref-type="ref"} Prophylaxis for delayed nausea remains an unmet medical need; the results of the current study suggest that regimens containing fosnetupitant at a dose of 235 mg could suppress such late‐onset nausea.

PK parameters demonstrated that fosnetupitant was eliminated rapidly from plasma and that netupitant reached a maximum plasma concentration at the end of infusion, suggesting that fosnetupitant is rapidly converted to netupitant, which is the active form. No remarkable differences in PK parameters were reported between patients in the United States and Japanese patients.[18](#cncr32429-bib-0018){ref-type="ref"} Therefore, it appears that fosnetupitant can be administered just before the administration of cisplatin.

The incidence and severity of AEs and treatment‐related AEs were found to be similar between the treatment groups, and the incidence in the fosnetupitant groups did not increase in a dose‐dependent manner. The AEs reported generally were those known to occur in patients receiving chemotherapy and palonosetron. Treatment‐related ISRs occurred in ≤1.0% of patients in the current study and were not reported to occur in a phase 1 study of fosnetupitant in healthy adults[7](#cncr32429-bib-0007){ref-type="ref"} conducted in Japan or in a phase 3 safety study of NEPA in initial and repeated cycles performed outside of Japan.[6](#cncr32429-bib-0006){ref-type="ref"} Based on these data, we believe fosnetupitant is unlikely to cause ISRs and that intravenous fosnetupitant can be administered safely.

To our knowledge, the current study is the first to demonstrate superior efficacy with the addition of fosnetupitant to palonosetron at a dose of 0.75 mg and dexamethasone in patients receiving cisplatin. A limitation of the current study was that the relative clinical efficacy of a fosnetupitant‐based regimen was unclear because this study did not include an active comparator.

Fosnetupitant in combination with palonosetron at a dose of 0.75 mg and dexamethasone was superior to palonosetron at a dose of 0.75 mg and dexamethasone alone in patients receiving cisplatin‐based chemotherapy. The recommended dose of fosnetupitant in this regimen is 235 mg, which is the same dose that was approved for use with palonosetron at a dose of 0.25 mg as a fixed‐dose combination regimen in the United States. We are planning to conduct a confirmatory study to verify the efficacy and safety of fosnetupitant versus an existing active comparator regimen.
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